Effectiveness and Immunogenicity of the MMR Vaccine Against SARS-CoV-2 Among Healthcare Workers

Viruses. 2025 Feb 1;17(2):215. doi: 10.3390/v17020215.

Abstract

The purpose of this study was to evaluate the effectiveness and immunogenicity of the measles-mumps-rubella (MMR) vaccine against SARS-CoV-2 in healthcare workers at one medical institution. The effectiveness of the MMR vaccine against SARS-CoV-2 was evaluated in overall healthcare workers (HCWs). In addition, neutralizing antibodies to SARS-CoV-2 were measured according to the subjects' measles immunity status with serum samples collected before the coronavirus disease 2019 pandemic period. The effectiveness of the MMR vaccine for SARS-CoV-2 in all HCWs and measles IgG-positive subjects was 34% (adjusted odds ratio [aOR] = 1.20, 95% confidence interval [CI] = 0.53-2.70) and 34% (aOR = 0.66, CI = 0.38-18.4), respectively. The neutralizing antibody levels for SARS-CoV-2 were low in all groups regardless of the measles immune status. The MMR vaccine alone may not provide sufficient protection against SARS-CoV-2.

Keywords: COVID-19; SARS-CoV-2; measles–mumps–rubella vaccine; vaccine effectiveness; vaccine immunogenicity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Neutralizing / blood
  • Antibodies, Neutralizing / immunology
  • Antibodies, Viral / blood
  • Antibodies, Viral / immunology
  • COVID-19* / immunology
  • COVID-19* / prevention & control
  • Female
  • Health Personnel* / statistics & numerical data
  • Humans
  • Immunogenicity, Vaccine*
  • Immunoglobulin G / blood
  • Male
  • Measles-Mumps-Rubella Vaccine* / administration & dosage
  • Measles-Mumps-Rubella Vaccine* / immunology
  • Middle Aged
  • SARS-CoV-2* / immunology
  • Vaccine Efficacy
  • Young Adult

Substances

  • Measles-Mumps-Rubella Vaccine
  • Antibodies, Viral
  • Antibodies, Neutralizing
  • Immunoglobulin G